Nektar Therapeutics | NKTR - Vertriebs- Und Verwaltungskosten





Vertriebs- Und Verwaltungskosten Veränderung Datum
Agios Pharmaceuticals USD 42.97M 1.7M 2025-12
ALKERMES USD 187.2M 15.43M 2025-12
Alterity Therapeutics Limited AUD 2.29M 649.1K 2023-06
Amgen USD 1.94B 237M 2025-12
Baxter International USD 761M 53M 2025-12
BioCryst Pharmaceuticals USD 80.47M 15.39M 2024-12
Biogen USD 545.2M 38.6M 2025-09
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Cara Therapeutics USD 4.64M 2.19M 2025-03
Cipla INR 13.25B 101.8M 2025-12
Dr.Reddys Laboratories INR 26.92B 482M 2025-12
Eisai JPY 111.72B 7.86B 2025-12
Eli Lilly USD 3.13B 391.3M 2025-12
Esperion Therapeutics USD 39.98M 4.21M 2024-09
Exelixis USD 123.02M 19.9M 2025-12
Gilead Sciences USD 1.78B 425M 2025-12
GlaxoSmithKline GBP 2.68B 518M 2025-12
Grifols EUR 333.1M 157M 2025-09
Halozyme Therapeutics USD 64.64M 27.11M 2025-12
Incyte USD 390.41M 61.33M 2025-12
Ionis Pharmaceuticals USD 130M 43.43M 2025-12
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
Karyopharm Therapeutics USD 27.19M 442K 2024-12
MacroGenics USD 9.9M 600K 2025-09
Merck USD 2.85B 215M 2025-12
Nektar Therapeutics USD -0.18 0.07 2024-09
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
Novartis USD 3.31B 134M 2025-09
Pfizer USD 4.08B 894M 2025-12
Roche Holding CHF 7.28B 3.99B 2025-12
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
Takeda JPY 282.78B 29.23B 2025-12
Teva Pharmaceutical Industries USD 1.12B 147M 2025-12
Xencor USD 17.04M 70.74M 2025-12